) U.S. consumer healthcare division, Chattem, Inc., recently
re-launched an over-the-counter antacid Rolaids in the U.S.
Rolaids is now available in both tablets and liquid formulation.
BAYER A G -ADR (BAYRY): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
We note that in Jan 2013, Sanofi acquired worldwide rights to
Rolaids from McNeil Consumer Healthcare, a subsidiary of
Johnson and Johnson
Sanofi is one of the major players in the consumer health care
market in the US. The company provides a strong platform for the
potential conversion of prescription medicines to OTC status in
the U.S. We are positive on the addition of Rolaids to Sanofi's
consumer healthcare portfolio, which includes products such as
Allegra over-the-counter, Icy Hot, Gold Bond, Cortizone-10,
Selsun Blue, ACT and Unisom.
Sanofi, a large-cap pharma company, carries a Zacks Rank #5
(Strong Sell). We are concerned about the generic threat
confronting most of Sanofi's key drugs. Additionally, recent
pipeline failures (oncology candidate - iniparib and
anticoagulant - otamixaban) have put immense pressure on Sanofi's
Additionally, Sanofi recently announced its decision to withdraw
the new drug application (NDA) for lixisenatide in the U.S.
Sanofi is looking to get the drug approved for the treatment of
adults with type II diabetes.
The NDA included early interim data from the ongoing ELIXA
cardiovascular (CV) outcomes study. The company believes that
potential public disclosure will hamper the integrity of the
ELIXA CV study, which is expected to be complete in the next 15
months. Sanofi intends to resubmit the NDA for lixisenatide in
2015, post completion of the ELIXA CV study.
Not all large-cap pharma companies are performing as badly as
) are well placed with a Zacks Rank #2 (Buy).